{"id":11480,"date":"2026-07-22T11:45:00","date_gmt":"2026-07-22T06:15:00","guid":{"rendered":"https:\/\/tradebrains.in\/money\/?p=11480"},"modified":"2026-07-22T12:11:48","modified_gmt":"2026-07-22T06:41:48","slug":"indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/","title":{"rendered":"India&#8217;s \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India&#8217;s Biopharma Expansion"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Synopsis<\/strong><em>: The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India&#8217;s ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government&#8217;s vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>India has gained fame for producing generic drugs and vaccines and is referred to as the<strong> \u201cpharmacy of the world.\u201d <\/strong>Advanced biopharmaceuticals, which include biologics, biosimilars, cell therapies, and precision medicines, are expected to be the next area of growth. The government has introduced the Biopharma SHAKTI program, which is a large-scale, systematic, and governmental effort to strengthen different segments of the biopharmaceutical market in India for the purpose of expanding research, production, and services in the biopharmaceutical sector.<\/p><div class=\"trade-content-3\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3981936055\"><a data-no-instant=\"1\" href=\"https:\/\/tradebrains.in\/get\/voltmoney\/\" rel=\"noopener\" class=\"a2t-link\" aria-label=\"LAMF3 300_250 (1)\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2025\/11\/LAMF3-300_250-1.png\" alt=\"\"  width=\"300\" height=\"250\"   \/><\/a><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-biopharma-shakti-programme\" style=\"font-size:22px\"><strong>What is Biopharma SHAKTI Programme?<\/strong><\/h2>\n\n\n\n<p>Biopharma SHAKTI (Strengthening and Accelerating Knowledge, Technology and Innovation) is a flagship program of the Government of India which is aimed at transforming the biopharmaceutical industry in India. Biopharma SHAKTI scheme is with an outlay of \u20b910,000 crore over five years and will address enhancement of research and development, proactively address increase in manufacturing, expedite the clinical trial process, and facilitate the entry of novel therapies to the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-drugs-will-be-made-and-developed\" style=\"font-size:22px\"><strong>What drugs will be made and developed?<\/strong><\/h2>\n\n\n\n<p>The Biopharma SHAKTI programme is geared towards the development and manufacturing of a broad spectrum of advanced biopharma products. These therapies are anticipated to be the major players in the field of treatment of complex and chronic diseases and to make India less reliant on foreign medicines. Major focus areas are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biosimilars:<\/strong> Generics of biologic drugs, which are used to treat cancer, diabetes and autoimmune diseases and are more affordable.<\/li>\n\n\n\n<li><strong>Monoclonal Antibodies: <\/strong>Therapies against a specific target, which are commonly used in oncology and immunology.<\/li>\n\n\n\n<li><strong>Vaccines:<\/strong> Next Generation Vaccine for Emerging Health Threats and Infectious Diseases.<\/li>\n\n\n\n<li><strong>Advanced therapies:<\/strong> that target rare genetic diseases and some cancers, known as cell and gene therapies.<\/li>\n\n\n\n<li><strong>Recombinant Proteins: <\/strong>Therapeutic proteins, for example insulin and growth hormones.<\/li>\n\n\n\n<li><strong>Fermentation-based Products: <\/strong>High value pharmaceutical ingredients and specialty biologics.<\/li>\n\n\n\n<li><strong>Drug Delivery Technologies: <\/strong>Innovative drug delivery systems that enhance treatment efficacy and patient results.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-companies-leading-india-s-biopharma-expansion\" style=\"font-size:22px\"><strong>Companies leading India\u2019s biopharma expansion<\/strong><\/h2>\n\n\n\n<p>The key players in the market are <strong>Biocon, Dr. Reddy&#8217;s Laboratories, Sun Pharma, Cipla, Serum Institute of India, Bharat Biotech, Zydus Lifesciences, Intas Pharmaceuticals, Biological E, and Lupin.<\/strong> These firms are funding biosimilars, monoclonal antibodies, vaccines, insulin products, oncology therapies, recombinant proteins and other advanced biologic medicines. As they intensify their research and development efforts, massive production and exporting to other nations, India is trying to increase its visibility in the high value pharmaceutical industry thereby decreasing reliance on imported biopharmaceuticals.<\/p><div class=\"trade-content\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-777485973\"><div translate=\"no\" class='mailmunch-forms-widget-1169732'><\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-state-wise-biopharma-manufacturing-hubs\" style=\"font-size:22px\"><strong>State-wise Biopharma manufacturing hubs<\/strong><\/h2>\n\n\n\n<p>The biopharma industry is concentrated in a few strong states and has a well-established ecosystem for research and development, manufacturing, and innovation in India.\u00a0<strong>Telangana, Karnataka, Maharashtra, Tamil Nadu and Gujarat <\/strong>are the leading biopharma states. Comprehend that Hyderabad Pharma City, Telangana, Genome Valley, Karnataka, Bengaluru, Maharashtra, Navi Mumbai, Pune, Chennai, Hosur, (Tamil Nadu), Ahmedabad, Vadodara, Ankleshwar (Gujarat) are major hubs for biologics, vaccines, biosimilars and advanced pharmaceutical manufacturing.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Also read<\/strong>: <a href=\"https:\/\/tradebrains.in\/money\/8-most-well-planned-areas-in-bangalore-for-quality-living-and-better-connectivity\/\" target=\"_blank\" rel=\"noreferrer noopener\">8 Most Well-Planned Areas in Bangalore for Quality Living and Better Connectivity<\/a><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-top-3-biopharma-manufacturing-states\" style=\"font-size:22px\"><strong>Top 3 Biopharma manufacturing states<\/strong><\/h2>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-1-telangana-biopharma-hub-of-india\" style=\"font-size:18px\"><strong>1. Telangana: Biopharma hub of India<\/strong><\/h2>\n\n\n\n<p>Telangana is the top biopharma state in India and Hyderabad is becoming a hub for pharmaceutical research, vaccine manufacturing and production of biologics. Some of the key locations are <strong>Genome Valley, Hyderabad Pharma City, Patancheru, Bollaram and Medchal.<\/strong> It is home to top industry giants like <strong>Dr. Reddy&#8217;s Laboratories, Bharat Biotech, Biological E, Aurobindo Pharma, Hetero and Laurus Labs.<\/strong> These companies specialize in vaccines, biosimilars, biologics, oncology drugs and other advanced therapies.<\/p><div class=\"trade-content-2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2590512051\"><a data-no-instant=\"1\" href=\"https:\/\/tradebrains.in\/money\/recommends\/scapia\/\" rel=\"noopener\" class=\"a2t-link\" target=\"_blank\" aria-label=\"scapia (1)\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2025\/12\/scapia-1.jpg\" alt=\"scapia (1)\"  srcset=\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2025\/12\/scapia-1.jpg 1000w, https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2025\/12\/scapia-1-980x980.jpg 980w, https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2025\/12\/scapia-1-480x480.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1000px, 100vw\" width=\"350\" height=\"350\"  style=\"display: inline-block;\" \/><\/a><\/div>\n\n\n\n<p>To bolster its position, Telangana has come up with the <strong>Next-Gen Life Sciences Policy 2026-30 <\/strong>and is building its life sciences ecosystem. The state wants to draw large investments, generate jobs and make Hyderabad a hub of biopharmaceutical innovations and manufacturing for the world.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-maharashtra-a-major-pharmaceutical-manufacturing-hub\" style=\"font-size:18px\"><strong>2. Maharashtra: A Major Pharmaceutical Manufacturing Hub<\/strong><\/h3>\n\n\n\n<p>Maharashtra is one of the biggest hubs for pharmaceuticals and biotechnology in India with major clusters in <strong>Mumbai, Navi Mumbai, Pune, Aurangabad and Nashik.<\/strong> The state has got a solid industrial base, research institutes, and access to international markets.<\/p>\n\n\n\n<p>Some of the top companies of the state are <strong>Sun Pharma, Cipla, Lupin, Glenmark Pharmaceuticals, Emcure Pharmaceuticals and Wockhardt.<\/strong> The companies produce a variety of products, such as biosimilars, vaccines, oncology drugs, respiratory therapies, and specialty pharmaceuticals. The state remains a source of investments in pharmaceutical manufacturing and research facilities, and Mumbai and Pune are key hubs for drug development, clinical research and biotechnology innovation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-3-gujarat-pharmaceutical-manufacturing-powerhouse-of-india\" style=\"font-size:18px\"><strong>3. Gujarat: Pharmaceutical Manufacturing powerhouse of India<\/strong><\/h3>\n\n\n\n<p>Gujarat is the largest pharmaceutical manufacturing state of India, contributing <strong>28% of the country&#8217;s total exports <\/strong>and <strong>33% of the total pharmaceutical production <\/strong>of the country. The state is a major contributor to India&#8217;s healthcare and life sciences sector with key major pharma clusters in <strong>Ahmedabad, Vadodara, Ankleshwar, Bharuch and Sanand.<\/strong><\/p>\n\n\n\n<p>Some of the prominent companies located in the state are <strong>Zydus Lifesciences, Torrent Pharmaceuticals, Intas Pharmaceuticals, Cadila Pharmaceuticals and Alembic Pharmaceuticals.<\/strong> These companies produce biosimilars, vaccines, APIs, specialty medicines and pharmaceutical formulations both domestically and internationally. Gujarat has an excellent industrial infrastructure and dedicated pharma manufacturing zones, which remain the reasons for investment in biotechnology and advanced drug manufacturing.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-expected-impact-of-biopharma-shakti-programme\" style=\"font-size:22px\"><strong>Expected Impact of Biopharma SHAKTI Programme<\/strong><\/h2>\n\n\n\n<p>The Biopharma SHAKTI programme aims to jumpstart India&#8217;s advancement from a global basis of middle-man generic pharmaceuticals to a supply of full-fledged advanced biopharmaceuticals. By funding research, manufacturing and the commercialization of advanced biopharmaceuticals, the programme aims to increase high-value biopharmaceuticals in India and decrease the dependence on imports.<\/p>\n\n\n\n<p>Investments, high-skilled job creation and an increase in biopharmaceutical exports and access to advanced therapies will all be a likely result of the programme. International competitiveness of biopharmaceuticals will likely be enhanced and improve advanced healthcare in India.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\" style=\"font-size:22px\"><strong>Conclusion<\/strong><\/h2>\n\n\n\n<p>The Biopharma SHAKTI initiative is building India&#8217;s capacity to lead in advanced biopharmaceuticals. The program looks to decrease the import of resources by enhancing research, manufacturing, and innovative partnerships and collaborations. From strong support from primary biopharma states and companies, the program has powerful prospects for India and its clients in the biopharma industry.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Synopsis: The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India&#8217;s ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government&#8217;s vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":11489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[8,14],"tags":[4015,4016,4017],"ppma_author":[2835],"class_list":["post-11480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-real-estate","category-trending","tag-biopharma-shakti","tag-biopharma-shakti-scheme","tag-india-biopharma-sector"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.3 (Yoast SEO v26.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>India&#039;s \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India&#039;s Biopharma Expansion<\/title>\n<meta name=\"description\" content=\"The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India&#039;s ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government&#039;s vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"India&#039;s \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India&#039;s Biopharma Expansion\" \/>\n<meta property=\"og:description\" content=\"The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India&#039;s ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government&#039;s vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Money\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T06:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T06:41:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jasmitha\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"India&#039;s \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India&#039;s Biopharma Expansion\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jasmitha\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/\",\"url\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/\",\"name\":\"India's \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India's Biopharma Expansion\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/money\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg\",\"datePublished\":\"2026-07-22T06:15:00+00:00\",\"dateModified\":\"2026-07-22T06:41:48+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/money\/#\/schema\/person\/175f6a77b57c97fbac1457377eac5d67\"},\"description\":\"The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India's ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government's vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#primaryimage\",\"url\":\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg\",\"contentUrl\":\"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg\",\"width\":1280,\"height\":854,\"caption\":\"Biopharma Shakti Scheme\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/money\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"India&#8217;s \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India&#8217;s Biopharma Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/money\/#website\",\"url\":\"https:\/\/tradebrains.in\/money\/\",\"name\":\"Trade Brains Money\",\"description\":\"Get the latest news on mutual funds, real estate and many more\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/money\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/money\/#\/schema\/person\/175f6a77b57c97fbac1457377eac5d67\",\"name\":\"Jasmitha\",\"description\":\"Jasmitha is a finance writer who loves to curate content on Personal Finance, credit cards, Real Estate and everyday investment decisions. She tracks the market regularly and decodes finance into simple, insight-driven narratives that help readers build clarity and make confident choices.\",\"url\":\"https:\/\/tradebrains.in\/money\/author\/jasmitha\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"India's \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India's Biopharma Expansion","description":"The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India's ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government's vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/","og_locale":"en_US","og_type":"article","og_title":"India's \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India's Biopharma Expansion","og_description":"The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India's ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government's vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.","og_url":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/","og_site_name":"Trade Brains Money","article_published_time":"2026-07-22T06:15:00+00:00","article_modified_time":"2026-07-22T06:41:48+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg","type":"image\/jpeg"}],"author":"Jasmitha","twitter_card":"summary_large_image","twitter_title":"India's \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India's Biopharma Expansion","twitter_misc":{"Written by":"Jasmitha","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/","url":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/","name":"India's \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India's Biopharma Expansion","isPartOf":{"@id":"https:\/\/tradebrains.in\/money\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg","datePublished":"2026-07-22T06:15:00+00:00","dateModified":"2026-07-22T06:41:48+00:00","author":{"@id":"https:\/\/tradebrains.in\/money\/#\/schema\/person\/175f6a77b57c97fbac1457377eac5d67"},"description":"The Union Budget 2026\u201327 proposed the Biopharma SHAKTI Scheme with an outlay of \u20b910,000 crore over five years to strengthen India's ecosystem for the production of biologics and biosimilars. The initiative is aligned with the government's vision of transforming India into a global biopharma leader and achieving a 5% share of the global biopharmaceutical market.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#primaryimage","url":"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg","contentUrl":"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/07\/Biopharma-Shakti-Scheme.jpg","width":1280,"height":854,"caption":"Biopharma Shakti Scheme"},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/money\/indias-10000-crore-biopharma-shakti-scheme-major-states-and-pharma-companies-leading-indias-biopharma-expansion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/money\/"},{"@type":"ListItem","position":2,"name":"India&#8217;s \u20b910,000 Crore Biopharma SHAKTI Scheme: Major States and Pharma Companies Leading India&#8217;s Biopharma Expansion"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/money\/#website","url":"https:\/\/tradebrains.in\/money\/","name":"Trade Brains Money","description":"Get the latest news on mutual funds, real estate and many more","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/money\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/money\/#\/schema\/person\/175f6a77b57c97fbac1457377eac5d67","name":"Jasmitha","description":"Jasmitha is a finance writer who loves to curate content on Personal Finance, credit cards, Real Estate and everyday investment decisions. She tracks the market regularly and decodes finance into simple, insight-driven narratives that help readers build clarity and make confident choices.","url":"https:\/\/tradebrains.in\/money\/author\/jasmitha\/"}]}},"authors":[{"term_id":2835,"user_id":15,"is_guest":0,"slug":"jasmitha","display_name":"Jasmitha","avatar_url":{"url":"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/04\/Boyapathi-Sai-Jasmitha.jpg","url2x":"https:\/\/tradebrains-wp.s3.ap-south-1.amazonaws.com\/money\/wp-content\/uploads\/2026\/04\/Boyapathi-Sai-Jasmitha.jpg"},"author_category":"1","first_name":"jasmitha","last_name":"Boyapati","user_url":"","job_title":"Financial Content Analyst","description":"<div>Jasmitha is a finance writer who loves to curate content on Personal Finance, credit cards, Real Estate and everyday investment decisions. She tracks the market regularly and decodes finance into simple, insight-driven narratives that help readers build clarity and make confident choices.<\/div>"}],"_links":{"self":[{"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/posts\/11480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/comments?post=11480"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/posts\/11480\/revisions"}],"predecessor-version":[{"id":11490,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/posts\/11480\/revisions\/11490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/media\/11489"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/media?parent=11480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/categories?post=11480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/tags?post=11480"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tradebrains.in\/money\/wp-json\/wp\/v2\/ppma_author?post=11480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}